Mesoblast Ltd (MSB)

1.685
+0.025(+1.51%)
  • Volume:
    1,180,586
  • Bid/Ask:
    1.685/1.690
  • Day's Range:
    1.650 - 1.693

MSB Overview

Prev. Close
1.66
Day's Range
1.65-1.693
Revenue
10.2M
Open
1.69
52 wk Range
1.5-5.05
EPS
-0.22
Volume
1,180,586
Market Cap
1.08B
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
3,059,821
P/E Ratio
-
Beta
3.18
1-Year Change
-51.18%
Shares Outstanding
648,089,834
Next Earnings Date
Nov 17, 2021
What is your sentiment on Mesoblast Ltd?
or
Vote to see community's results!

Mesoblast Ltd News

Mesoblast Ltd Analysis

  • Markets Limp Towards Yellen’s Friday Speech
    • ByIG-

    The DXY US dollar index gained 0.2%The Kiwi dollar was the best performing G-10 currency gaining 0.4%The Aussie was basically flat on the session holding US$0.7612WTI oil...

  • QuickView: Mesoblast

    Mesoblast’s (MSB.AX) current valuation assumes a high probability of success for its stem cell technology, but it does hold the leadership position in this field. A proposed...

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesBuyStrong BuyStrong BuyNeutralStrong Sell
Technical IndicatorsStrong BuyStrong BuyStrong BuyStrong BuyStrong Sell
SummaryStrong BuyStrong BuyStrong BuyBuyStrong Sell

Mesoblast Ltd Company Profile

Mesoblast Ltd Company Profile

Employees
83
Market
Australia

Mesoblast Limited is engaged in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The Company is using its mesenchymal lineage cell technology platform to develop and commercialize allogeneic cellular medicines to treat complex inflammatory diseases. Its product candidate includes Remestemcel-L ((RYONCIL) for the treatment of steroid-refractory acute graft versus host disease (SR-aGVHD), Rexlemestrocel-L (REVASCOR) for the advanced chronic heart failure (CHF) and MPC-06-ID for the treatment of chronic low back pain caused by disc degeneration (CLBP). Its product candidate MPC-150-IM for the treatment or prevention of chronic heart failure and MPC-25-IC for the treatment or prevention of acute myocardial infarction. Its product candidate also includes MPC-300-IV for the treatment of biologic-refractory rheumatoid arthritis and diabetic nephropathy.

Read More
  • whys this company worth so much more on the NASDAQ?
    0
    • 1meso = 5msb
      0
    • Daniel Ma how does that work?
      0
    • No it is 4 Australian MESO stock = 1 NASDAQ MESO Stock.
      0
  • Rocket in 2 weeks
    2
    • $4.1 now from $3. This is still notbing compared to next few weeks :)
      1
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.